- Home
- ICCM vs MCRB Comparison
ICCM vs MCRB Comparison
Compare ICCM & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- MCRB
- Stock Information
- Founded
- ICCM 2006
- MCRB 2010
- Country
- ICCM Israel
- MCRB United States
- Employees
- ICCM N/A
- MCRB N/A
- Industry
- ICCM
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- MCRB Health Care
- Exchange
- ICCM Nasdaq
- MCRB Nasdaq
- Market Cap
- ICCM 61.0M
- MCRB 72.0M
- IPO Year
- ICCM N/A
- MCRB 2015
- Fundamental
- Price
- ICCM $1.05
- MCRB $7.00
- Analyst Decision
- ICCM Strong Buy
- MCRB Hold
- Analyst Count
- ICCM 1
- MCRB 5
- Target Price
- ICCM $2.50
- MCRB $73.67
- AVG Volume (30 Days)
- ICCM 254.9K
- MCRB 93.5K
- Earning Date
- ICCM 05-28-2025
- MCRB 05-07-2025
- Dividend Yield
- ICCM N/A
- MCRB N/A
- EPS Growth
- ICCM N/A
- MCRB N/A
- EPS
- ICCM N/A
- MCRB 8.98
- Revenue
- ICCM $3,273,000.00
- MCRB N/A
- Revenue This Year
- ICCM $85.75
- MCRB N/A
- Revenue Next Year
- ICCM $189.92
- MCRB N/A
- P/E Ratio
- ICCM N/A
- MCRB $0.78
- Revenue Growth
- ICCM 0.34
- MCRB N/A
- 52 Week Low
- ICCM $0.48
- MCRB $6.53
- 52 Week High
- ICCM $1.66
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- ICCM 46.97
- MCRB 38.60
- Support Level
- ICCM $0.99
- MCRB $7.32
- Resistance Level
- ICCM $1.14
- MCRB $7.33
- Average True Range (ATR)
- ICCM 0.07
- MCRB 0.59
- MACD
- ICCM 0.01
- MCRB 0.09
- Stochastic Oscillator
- ICCM 64.00
- MCRB 26.11
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.